What is the 13F Pro Quality Score for BMEA?

13F Pro ranks Biomea Fusion, Inc. (BMEA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BMEA's current score at https://13fpro.ai/research/BMEA (free sign-up required for the full ranking).

Which hedge funds own the most BMEA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BMEA include FMR, VANGUARD CAPITAL MANAGEMENT, Aisling Capital Management. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BMEA as soon as new 13F filings post.

Where does 13F Pro source BMEA data?

All Biomea Fusion, Inc. fundamentals and ownership data come directly from SEC EDGAR. Biomea Fusion, Inc. files with the SEC under CIK 1840439. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BMEA in?

Biomea Fusion, Inc. (BMEA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BMEA research updated on 13F Pro?

BMEA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Biomea Fusion, Inc.(BMEA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1840439 BMEA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BMEA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Biomea Fusion, Inc. (BMEA), a Healthcare sector company. BMEA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Biomea Fusion, Inc. reports net income of $-12.4M, free cash flow of $-11.7M. Top institutional holders of BMEA by reported 13-F value include FMR, VANGUARD CAPITAL MANAGEMENT, Aisling Capital Management, based on the most recent SEC filings. BMEA trades on the Nasdaq exchange and files with the SEC under CIK 1840439. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMEA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Biomea Fusion, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-12.4M

Free Cash Flow

Q1 2026

$-11.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+55.4% YoY

$-61.8MFY 2025

FY22 $-81.8MFY23 $-117.3MFY24 $-138.4MFY25 $-61.8M

Operating Income

+42.0% YoY

$-83.5MFY 2025

FY22 $-83.6MFY23 $-126.1MFY24 $-144.1MFY25 $-83.5M

EPS (Diluted)

+69.2% YoY

$-1.18FY 2025

FY22 $-2.80FY23 $-3.44FY24 $-3.83FY25 $-1.18

Total Assets

-26.7% YoY

$58.6MFY 2025

FY22 $129.3MFY23 $199.9MFY24 $79.9MFY25 $58.6M

Op. Cash Flow

+41.3% YoY

$-70.4MFY 2025

FY22 $-62.4MFY23 $-96.6MFY24 $-119.9MFY25 $-70.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-61.8M +55.4%	$-138.4M -18.1%	$-117.3M -43.3%	$-81.8M -96.9%	$-41.6M -680.7%	$-5.3M
Operating Income	$-83.5M +42.0%	$-144.1M -14.2%	$-126.1M -50.8%	$-83.6M -100.7%	$-41.7M -682.2%	$-5.3M
EPS (Diluted)	$-1.18 +69.2%	$-3.83 -11.3%	$-3.44 -22.9%	$-2.80 -60.9%	$-1.74 -2915.6%	$-0.06
Total Assets	$58.6M -26.7%	$79.9M -60.0%	$199.9M +54.6%	$129.3M -30.4%	$185.7M +197.0%	$62.5M
Operating Cash Flow	$-70.4M +41.3%	$-119.9M -24.1%	$-96.6M -54.8%	$-62.4M -76.1%	$-35.4M -694.8%	$-4.5M

AI Insight: BMEA Financial Trends

Equity has collapsed from $104M to $19M over six quarters as BMEA burns cash with zero revenue, though quarterly losses are narrowing sharply.

• Net loss narrowed dramatically from -$37M in Q2 2024 to -$12M in Q1 2026, a 68% reduction in quarterly losses.

• Equity eroded from $104M in Q2 2024 to $19M in Q1 2026, reflecting sustained cash consumption with no revenue offset.

• Operating cash outflow improved from -$33M in Q2 2024 to -$12M in Q1 2026, suggesting meaningful cost discipline over the period.

• Q4 2025 showed a one-quarter net income swing to +$5M, but Q1 2026 returned to -$12M net loss, signaling the profit was non-recurring.

⚠ Equity at $19M in Q1 2026 with -$12M quarterly cash burn implies fewer than two quarters of runway absent new financing.

⚠ No revenue across all eight quarters; any catalyst triggering a partnership or milestone payment would be a critical inflection point.

⚠ Q4 2025's anomalous +$5M net income warrants scrutiny — operating income remained -$12M, suggesting a below-the-line, possibly non-cash, item.

AI Insight: BMEA Ratio Trends

Data is too sparse to establish reliable profitability trends; only isolated ROE and ROA readings are available across nine periods.

• ROE swung from -143.4% in Q2 2024 to -172.6% in Q3 2024, then rebounded sharply to +62.4% in Q4 2025.

• ROA turned positive at 31.5% in Q4 2025, the only non-negative ROA reading in the dataset.

⚠ TTM ROA stands at -96.9%, contrasting with Q4 2025's +31.5% — suggesting Q4 2025 may reflect a one-off item.

⚠ OpMargin, NPM, ROIC, and D/E are entirely absent — insufficient data to assess operating efficiency or leverage.

Get alerted when BMEA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Biomea Fusion, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BMEA

FMR LLC
$13.5M8,813,359 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.0M2,597,300 sh
Aisling Capital Management LP
$3.1M2,048,757 sh
RENAISSANCE TECHNOLOGIES LLC
$2.0M1,312,798 sh
MARSHALL WACE, LLP
$1.8M1,198,551 sh
CITADEL ADVISORS LLC
$1.0M656,817 sh
Mariner, LLC
$1.0M654,578 sh
BlackRock, Inc.
$981.4K641,435 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$963.7K629,865 sh
FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.
$852.3K557,036 sh

Fund	Value	Shares
FMR LLC	$13.5M	8,813,359
VANGUARD CAPITAL MANAGEMENT LLC	$4.0M	2,597,300
Aisling Capital Management LP	$3.1M	2,048,757
RENAISSANCE TECHNOLOGIES LLC	$2.0M	1,312,798
MARSHALL WACE, LLP	$1.8M	1,198,551
CITADEL ADVISORS LLC	$1.0M	656,817
Mariner, LLC	$1.0M	654,578
BlackRock, Inc.	$981.4K	641,435
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$963.7K	629,865
FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.	$852.3K	557,036

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BMEA on your watchlist

Track score changes the day Biomea Fusion, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BMEA a good stock to buy?

13F Pro's AI-powered analysis of Biomea Fusion, Inc. (BMEA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BMEA are available on the BMEA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BMEA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BMEA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Biomea Fusion, Inc.'s investment landscape.